Georgia Medicare Transplant Services Coverage

::: hero

By Brevy Care Team · Last verified May 13, 2026

Organ transplantation is the most clinically complex, financially expensive, and ethically intricate category of medical care that Medicare covers. For older Americans, transplant care is not a rare or fringe service: a significant and growing proportion of kidney, heart, and liver transplant recipients are Medicare beneficiaries, and first-year transplant costs run into the hundreds of thousands of dollars.

Medicare's coverage of transplant care is governed by an unusually intricate statutory and regulatory framework spanning multiple titles of the Social Security Act, multiple parts of the Code of Federal Regulations, multiple National Coverage Determinations, and a separate organ allocation system administered by the United Network for Organ Sharing under contract with the federal Health Resources and Services Administration. Section 1881(b) of the Social Security Act, added by Public Law 92-603 in 1972, establishes Medicare entitlement for individuals with end-stage renal disease regardless of age, providing the only Medicare entitlement pathway tied to a specific disease rather than age or disability duration. Section 1861(s)(2)(J) places immunosuppressive drugs for Medicare-paid transplants under Part B rather than Part D. Section 402 of the Consolidated Appropriations Act 2021, Public Law 116-260, signed by President Trump on December 27, 2020, with the immunosuppressive drug provision effective January 1, 2023, created the Part B-ID (Part B Immunosuppressive Drug) benefit that permanently extends immunosuppressive coverage beyond the 36-month post-kidney-transplant ESRD termination cutoff, the most significant transplant-related Medicare expansion in decades.

Heart transplant coverage is governed by National Coverage Determination 260.9, originally promulgated in 1986. Liver transplant by NCD 260.1. Intestinal and multi-visceral transplant by NCD 260.4. Stem cell transplantation including bone marrow, peripheral blood stem cell, and umbilical cord blood by NCD 110.8.1. Lung and heart-lung by Section 1861(s)(2)(P) and associated coverage policies. Each organ has organ-specific Medicare-approved transplant center designation requirements under 42 CFR 482.68 through 482.104, the Transplant Center Conditions of Participation promulgated in the 2007 final rule effective June 28, 2008. Centers must meet minimum case volumes, outcome benchmarks based on risk-adjusted Scientific Registry of Transplant Recipients modeling, and detailed organizational and clinical standards. Loss of Medicare approval means Medicare beneficiaries cannot use the center for Medicare-paid transplants.

The Georgia transplant ecosystem is anchored by Emory Transplant Center (kidney since 1966, liver since 1987, heart since 1985, lung since 1993, pancreas, stem cell), Piedmont Transplant Institute (kidney, liver), Augusta University Transplant (adult and limited pediatric kidney), and Children's Healthcare of Atlanta (pediatric kidney, heart, liver, stem cell). LifeLink of Georgia is the federally designated organ procurement organization for the state, recovering organs from deceased donors, managing tissue typing and crossmatching, transporting organs to centers, and billing transplant centers for acquisition costs under the Section 1861(v)(1)(F) reasonable cost methodology.

This guide is published by Brevy, the eldercare resource at brevy.com helping Georgia families navigate the complex intersection of Medicare entitlement pathways, organ-specific National Coverage Determinations, Medicare-approved transplant center designation, organ acquisition cost reimbursement, the Section 402 Part B-ID immunosuppressive drug benefit, UNOS allocation, post-transplant care coordination, and the practical realities of pursuing transplant care in Georgia. The information here is general educational content reflecting federal law and regulation as of May 2026. It is not personalized medical advice, transplant candidacy evaluation, or legal counsel. For specific transplant evaluation, contact the Emory Transplant Center at 855-366-7989, the Piedmont Transplant Institute at 404-605-3232, Augusta University Transplant at 706-721-2888, or Children's Healthcare of Atlanta Transplant Services at 404-785-4150. For Medicare ESRD entitlement and Part B-ID enrollment, contact Medicare at 1-800-MEDICARE or the GeorgiaCares State Health Insurance Assistance Program at 1-866-552-4464. :::

::: callout Key Takeaways

1. Section 1881(b) of the Social Security Act, added by Public Law 92-603 in 1972 (the Social Security Amendments of 1972), establishes Medicare entitlement for individuals with end-stage renal disease regardless of age. This is the only Medicare entitlement pathway tied to a specific disease. ESRD Medicare begins in the 4th month of maintenance dialysis, or in the month of kidney transplant (or up to 2 months prior if hospitalized for transplant preparation). Historically, ESRD-based Medicare entitlement terminated 36 months after successful kidney transplant.

2. Section 402 of the Consolidated Appropriations Act 2021, Public Law 116-260, signed by President Trump on December 27, 2020, with the immunosuppressive drug provision effective January 1, 2023, created Medicare Part B-ID (Part B Immunosuppressive Drug benefit). Part B-ID permanently extends immunosuppressive drug coverage indefinitely beyond the 36-month ESRD termination cutoff, eliminating the prior gap that forced kidney transplant recipients to choose between paying $10,000 to $25,000 per year out of pocket for immunosuppressives or losing their transplant. Part B-ID has its own monthly premium, its own annual deductible, and 20 percent coinsurance.

3. Section 1861(s)(2)(J) places immunosuppressive drugs for Medicare-paid transplants under Part B rather than Part D. This means 20 percent coinsurance, no Part D coverage gap exposure, and the option to have Part B coinsurance covered by a Medigap plan. Covered immunosuppressives include tacrolimus (Prograf, Astagraf, Envarsus), cyclosporine (Sandimmune, Neoral, Gengraf), sirolimus (Rapamune), everolimus (Zortress), mycophenolate (CellCept, Myfortic), azathioprine (Imuran), prednisone, basiliximab (Simulect, HCPCS J0480), antithymocyte globulin (Thymoglobulin, HCPCS J7504), belatacept (Nulojix, HCPCS J0490), and rituximab (Rituxan, HCPCS J9312) for antibody-mediated rejection.

4. Heart transplant is governed by National Coverage Determination 260.9 (originally 1986). Coverage requires end-stage cardiac disease with prognosis under 12 months, absence of contraindications (active infection, recent malignancy, irreversible pulmonary hypertension, severe peripheral vascular disease, irreversible renal or hepatic dysfunction), and performance at a Medicare-approved heart transplant center. In Georgia, Emory University Hospital is the only Medicare-approved heart transplant center.

5. Liver transplant is governed by NCD 260.1. Coverage requires end-stage liver disease (cirrhosis from any cause, primary biliary cholangitis, primary sclerosing cholangitis, hepatocellular carcinoma within Milan or expanded criteria, acute liver failure), documented alcohol abstinence for alcohol-related liver disease (historically 6 months minimum; some centers now permit earlier transplant for severe alcohol-associated hepatitis with mandatory addiction treatment), and performance at a Medicare-approved liver transplant center. In Georgia, Emory and Piedmont are the two Medicare-approved adult liver transplant centers.

6. Lung and heart-lung transplant is covered under Section 1861(s)(2)(P) and associated coverage policies. Indications include idiopathic pulmonary fibrosis, COPD, cystic fibrosis, pulmonary hypertension, and other end-stage pulmonary disease. Bilateral lung transplant is generally preferred for younger, healthier candidates; single lung for older patients with comorbidities. Emory is the only Medicare-approved lung transplant center in Georgia.

7. Stem cell transplantation is covered under NCD 110.8.1 including allogeneic and autologous transplants for acute leukemia (AML, ALL), chronic myeloid leukemia, multiple myeloma (autologous), lymphomas, myelodysplastic syndrome, severe aplastic anemia, sickle cell disease (recent expansion), and selected non-malignant conditions. Emory Winship Cancer Institute, Northside Hospital Atlanta, and Children's Healthcare of Atlanta are the primary Georgia stem cell transplant programs.

8. 42 CFR 482.68 through 482.104 establish the Medicare Transplant Center Conditions of Participation (final rule June 28, 2007, effective June 28, 2008). Centers must meet organ-specific minimum case volumes during 12-month evaluation periods, achieve 1-year patient and graft survival within statistically expected range based on risk-adjusted SRTR modeling, and meet detailed clinical and organizational standards. Failure can result in loss of Medicare approval. Organ acquisition costs are paid on a reasonable cost basis under Section 1861(v)(1)(F) rather than bundled into DRG payment, recognizing the logistical and clinical uniqueness of organ procurement. The Standard Acquisition Charge is calculated per organ program and paid by Medicare separately from the inpatient DRG payment. LifeLink of Georgia (404-636-1100) is the federally designated organ procurement organization for the state of Georgia, recovering organs from deceased donors and managing the procurement chain. :::

The clinical and economic landscape of Georgia Medicare transplant care

Consider Margaret, a 67-year-old retired Atlanta Public Schools teacher with a 14-year history of type 2 diabetes complicated by diabetic nephropathy. Over the past 6 years her estimated glomerular filtration rate has declined from 45 to 12 ml/min/1.73m². She began maintenance hemodialysis 8 months ago through Fresenius Kidney Care at a clinic 20 minutes from her Decatur home, traveling three mornings per week for four-hour sessions. Margaret has Medicare based on age (enrolled at 65) and a Medigap Plan G policy with BlueCross BlueShield. Her nephrologist at Emory referred her for kidney transplant evaluation 4 months into dialysis. After a multi-month evaluation including cardiac workup (stress echocardiogram, cardiac catheterization given diabetes), oncologic screening (mammography, colonoscopy, dermatologic evaluation), dental clearance (Medicare did not cover; Margaret paid $1,200 out of pocket for crown work required before listing), infectious disease screening (CMV, EBV, HIV, hepatitis panel, latent TB testing with quantiferon), surgical evaluation, and psychosocial evaluation, Margaret is listed for deceased-donor kidney transplant at Emory with an EPTS (Estimated Post-Transplant Survival) score in the top 20 percent. She is also pursuing two potential living donors (her daughter and a longtime friend) who are undergoing their own evaluations.

The financial reality of Margaret's transplant pathway: when transplant occurs, Medicare will pay Emory University Hospital an inpatient prospective payment system payment under DRG 008 (Simultaneous Pancreas/Kidney Transplant) or DRG 652 (Kidney Transplant) of approximately $120,000 to $150,000 for the hospitalization. Separately, Medicare will pay Emory a Standard Acquisition Charge of approximately $95,000 covering organ procurement costs incurred by LifeLink of Georgia and Emory's recipient and donor evaluation overhead. Post-transplant, Margaret will require lifetime immunosuppressive medications: tacrolimus (typical maintenance dose 4 to 6 mg twice daily, generic cost approximately $300 per month before insurance), mycophenolate mofetil (typical dose 1000 mg twice daily, generic cost approximately $200 per month), and prednisone (typical maintenance 5 mg daily, generic cost approximately $5 per month). Annual immunosuppressive cost: approximately $6,000 at generic pricing. Medicare Part B will cover these drugs at 80 percent (under Section 1861(s)(2)(J)) with the remaining 20 percent covered by Margaret's Medigap Plan G after a small annual Plan G deductible. Margaret's lifetime out-of-pocket cost for immunosuppressives is essentially $0 because her Medicare and Medigap coverage are both intact based on her age-65 Medicare entitlement (not ESRD-based, so the 36-month ESRD termination does not apply to her).

Margaret's story is increasingly typical. A growing proportion of kidney transplant recipients are age 65 or older, and transplant centers have become more comfortable with older recipients as outcomes data demonstrate that age alone does not predict poor transplant survival. The population of older Americans with ESRD has grown alongside the aging of the diabetic and hypertensive baby-boom cohort. Georgia has a substantial ESRD population, with thousands of residents on maintenance dialysis, living with functioning kidney transplants, or on the transplant waiting list.

Beyond kidney, the Georgia transplant population includes heart transplant recipients (Emory is the sole Medicare-approved heart program in Georgia), liver transplant recipients (Emory and Piedmont are the two Medicare-approved adult liver centers), lung transplant recipients (Emory is the sole Medicare-approved lung program), pancreas transplant recipients (typically simultaneous pancreas-kidney for diabetics with ESRD at Emory), and stem cell transplant recipients (Emory Winship, Northside, and CHOA are the primary Georgia programs for hematologic malignancies and selected non-malignant conditions). Each of these populations carries lifetime Medicare implications: lifelong immunosuppressive needs, intensive post-transplant follow-up, risk of rejection requiring biopsies and treatment, risk of opportunistic infection requiring antimicrobial prophylaxis and treatment, malignancy surveillance, and the ongoing economic considerations of being a Medicare transplant recipient in Georgia.

Section 1881(b) of the Social Security Act: ESRD Medicare entitlement and the kidney transplant pathway

Section 1881 of the Social Security Act, added by Public Law 92-603 (the Social Security Amendments of 1972), created the most distinctive expansion of Medicare in the program's history: entitlement based not on age, not on disability duration, but on a specific medical condition. The 1972 ESRD provision recognized that the cost of maintenance dialysis was beyond the means of virtually every individual or family, that without dialysis ESRD was uniformly fatal within weeks, and that no other major payer was willing to absorb the cost. By extending Medicare to all ESRD patients regardless of age, Congress created a universal payer of last resort for a specific catastrophic disease, the only such provision in American health care. Section 1881(b) governs payment to providers for the spectrum of ESRD services including maintenance dialysis (in-center hemodialysis, peritoneal dialysis, home hemodialysis), kidney transplant services, post-transplant care, and immunosuppressive drugs (primarily through cross-reference to Section 1861(s)(2)(J)).

Timing of ESRD Medicare entitlement

The Section 1881 ESRD Medicare entitlement timing rules are precise and operationally important. For an individual beginning maintenance dialysis, Medicare entitlement begins in the 4th month of dialysis: the first three months are the "3-month waiting period" during which the beneficiary either pays for dialysis privately, uses private insurance if available, or relies on Medicaid for dual-eligibles. The 3-month waiting period was originally adopted to encourage transplantation (the idea being that patients who would be transplanted quickly might never need Medicare); in modern practice, the 3-month waiting period is widely viewed as anachronistic given that virtually no patient receives a transplant within 90 days of dialysis initiation.

The 3-month waiting period is waived in two situations: (1) for patients who begin home dialysis training (peritoneal dialysis training or home hemodialysis training) during the first three months, Medicare entitlement begins in the 1st month of dialysis; and (2) for patients who receive a kidney transplant within the first three months without having undergone maintenance dialysis, Medicare entitlement begins in the month of transplant or up to 2 months before if the patient was hospitalized for transplant preparation. These waivers create modest incentives for home dialysis modalities and for preemptive transplantation.

Termination of ESRD-based Medicare entitlement

Section 1881 entitlement does not last indefinitely. For dialysis patients whose dialysis ceases (because the patient receives a successful transplant, recovers kidney function, or stops dialysis for other reasons including death), Medicare ESRD entitlement terminates 12 months after the month dialysis ceases. For successful kidney transplant recipients, ESRD-based Medicare entitlement historically terminated 36 months after the month of transplant. This 36-month termination applied only to individuals whose sole basis for Medicare was ESRD. Beneficiaries with concurrent Medicare entitlement based on age 65+ or based on SSDI disability for 24+ months retained Medicare under those alternative entitlements regardless of transplant outcome.

The 36-month ESRD termination created a notorious policy problem. Kidney transplant recipients require lifelong immunosuppressive drugs costing $10,000 to $25,000 per year at retail. When ESRD-based Medicare ended at month 37 post-transplant, recipients lost coverage for these drugs. Documented cases accumulated of patients stopping immunosuppressives due to cost, experiencing transplant rejection, returning to dialysis (re-establishing Medicare entitlement), and then requiring re-transplantation (which Medicare paid for again at $442,500 per transplant). The cycle was economically irrational for the Medicare program and clinically tragic for patients. Patient advocacy groups (the National Kidney Foundation, the American Kidney Fund, the American Society of Transplantation, and the American Society of Transplant Surgeons) sought a statutory fix for over two decades.

Section 402 of the Consolidated Appropriations Act 2021: the permanent immunosuppressive drug extension

Section 402 of the Consolidated Appropriations Act 2021, Public Law 116-260, signed by President Trump on December 27, 2020, with the immunosuppressive drug provision effective January 1, 2023, created Medicare Part B-ID (Part B Immunosuppressive Drug benefit). Part B-ID is a standalone Medicare benefit covering only immunosuppressive drugs for kidney transplant recipients who would otherwise lose Medicare entitlement at 36 months post-transplant under Section 1881.

Part B-ID eligibility: A beneficiary qualifies for Part B-ID if (1) they received a kidney transplant for which Medicare paid (Part A or Part B), (2) their broader Medicare entitlement has ended (typically after the 36-month ESRD post-transplant cutoff), (3) they are not enrolled in other "creditable coverage" providing immunosuppressive drugs (some group health plans, Medicaid, or other federal programs may constitute creditable coverage), and (4) they enroll during their initial enrollment period (the 8 months surrounding their Medicare termination) or during a subsequent special enrollment period for loss of creditable coverage.

Part B-ID structure: Part B-ID covers only immunosuppressive drugs (not other Medicare services). Beneficiaries pay a monthly premium, an annual deductible, and 20 percent coinsurance on covered immunosuppressives. The 20 percent coinsurance may be covered by Medigap if the beneficiary holds a Medigap policy. For low-income beneficiaries, Part B-ID premium and cost-sharing assistance is available through state Medicaid programs (Georgia Medicaid through DCH at 1-866-211-0950 can provide Medicare Savings Program assistance for Part B-ID premiums for qualifying dual-eligibles).

Part B-ID significance: Section 402 was supported by every major transplant professional society, every patient advocacy group, and broad bipartisan congressional support spanning over two decades of legislative effort. It was the most significant transplant-related Medicare expansion since the original Section 1881 ESRD entitlement in 1972. CMS projects gradual enrollment growth as the post-transplant population whose ESRD-based Medicare terminated continues to age.

Section 1833(b)(1) does not apply to transplant services: the broader Medicare framework

For age-65 or SSDI-based Medicare beneficiaries who undergo transplant, the standard Medicare framework applies. Part A (Section 1812) covers the inpatient transplant admission under DRG-based prospective payment. Part B (Section 1832) covers outpatient pre-transplant evaluation, post-transplant follow-up visits, physician services, outpatient hospital services, and Part B drugs including immunosuppressives. Standard cost-sharing applies: Part A inpatient deductible, Part B annual deductible, 20 percent Part B coinsurance, and the various coordination rules with Medigap, Medicare Advantage, and Medicaid for dual-eligibles.

Section 1861(s)(2)(J): immunosuppressive drugs as a Part B benefit

Section 1861(s)(2)(J) places immunosuppressive drugs for Medicare-paid transplants under Part B rather than Part D. This placement has significant practical consequences. 20 percent Part B coinsurance applies rather than Part D's variable cost-sharing structure. No Part D coverage gap (donut hole) exposure: Part B drugs are not subject to the Part D coverage gap that historically created a window of higher beneficiary cost-sharing before catastrophic protection kicked in. Medigap coverage: many Medigap plans cover Part B coinsurance, effectively eliminating the patient's out-of-pocket cost for Part B-covered immunosuppressives. Different prior authorization rules: Part B medical benefit prior authorization differs from Part D pharmacy benefit prior authorization; transplant centers' transplant pharmacists often manage Part B authorization directly.

Covered immunosuppressive drugs

Calcineurin inhibitors: tacrolimus (Prograf, Astagraf XL, Envarsus XR) is the workhorse maintenance immunosuppressive for most kidney, liver, heart, lung, and pancreas transplants. Cyclosporine (Sandimmune, Neoral, Gengraf) is used less frequently in modern practice but remains covered.

mTOR inhibitors: sirolimus (Rapamune) and everolimus (Zortress) are alternative maintenance agents, often used for patients with calcineurin inhibitor toxicity or for tumor surveillance benefits.

Antimetabolites: mycophenolate mofetil (CellCept) and mycophenolic acid (Myfortic) are standard antiproliferative agents used in combination with calcineurin inhibitors. Azathioprine (Imuran) is an older alternative used in selected patients.

Corticosteroids: prednisone and methylprednisolone are used for induction (high doses peri-transplant), maintenance (low doses long-term), and rejection treatment (pulse doses).

Biologic induction agents (HCPCS J-codes for IV administration):

• J0480 basiliximab (Simulect): anti-IL-2 receptor monoclonal antibody, used as induction immunosuppression at time of transplant
• J7504 antithymocyte globulin (Thymoglobulin, rabbit ATG): polyclonal antibody used for induction and severe rejection treatment
• J0490 belatacept (Nulojix): CTLA-4 fusion protein used as calcineurin-inhibitor-sparing maintenance therapy in selected kidney transplant patients
• J9312 rituximab (Rituxan): anti-CD20 monoclonal antibody used for antibody-mediated rejection and desensitization
• J1300 eculizumab (Soliris): complement C5 inhibitor used for atypical hemolytic uremic syndrome including post-transplant recurrence

Heart transplant: NCD 260.9 and the Emory program

National Coverage Determination 260.9 (Heart Transplants) was first promulgated by CMS in 1986 establishing Medicare coverage for heart transplantation. The NCD has been updated several times to reflect evolving clinical practice. Current coverage criteria include end-stage cardiac disease with prognosis of less than 12-month survival without transplant, absence of contraindications (active infection, recent malignancy with active disease, irreversible pulmonary hypertension with elevated pulmonary vascular resistance, severe peripheral vascular disease that would compromise post-transplant outcomes, irreversible renal or hepatic dysfunction not addressable by combined organ transplant), and performance at a Medicare-approved heart transplant center meeting the 42 CFR 482.70 organ-specific Conditions of Participation.

Heart allocation operates under the 2018 six-tier urgency system that replaced the prior three-tier system. Status 1 (highest urgency) includes patients on mechanical circulatory support who cannot be discharged or who are experiencing device complications. Status 6 (lowest urgency) includes stable candidates with relatively preserved function. The 2018 reform was driven by concern that the prior system had become gameable, with centers escalating clinical interventions specifically to qualify patients for higher status, and the new system attempts to align urgency tiers more closely with objective clinical markers.

Emory University Hospital is the only Medicare-approved heart transplant center in Georgia. The Emory Heart Transplant Program has performed heart transplants since 1985 and is one of the higher-volume heart programs in the Southeast. The Emory program also operates ventricular assist device (VAD) implantation services that serve as a bridge to transplant or destination therapy for patients ineligible for transplant. Heart transplant in Georgia requires referral to Emory and a multi-month evaluation including cardiopulmonary exercise testing, right heart catheterization with assessment of pulmonary vascular resistance, multidisciplinary review at heart transplant selection committee, and listing through UNOS upon committee approval.

Liver transplant: NCD 260.1 and the Emory/Piedmont programs

National Coverage Determination 260.1 (Liver Transplants) establishes Medicare coverage for liver transplantation. Coverage indications include end-stage liver disease from various causes: chronic hepatitis C (now largely curable but with cirrhosis sometimes irreversible), alcohol-associated liver disease, non-alcoholic steatohepatitis (NASH) which has become the leading transplant indication, primary biliary cholangitis, primary sclerosing cholangitis, hepatocellular carcinoma within Milan criteria (single tumor <5 cm or up to 3 tumors each <3 cm) or expanded UCSF criteria, acute liver failure (rapid evaluation and Status 1A listing), and selected metabolic and genetic conditions.

For alcohol-associated liver disease, Medicare and most transplant centers historically required documented abstinence of at least 6 months before listing. Modern practice has evolved with growing recognition that severe alcohol-associated hepatitis (the acute presentation) often does not allow a 6-month wait without death intervening. Some centers, including Emory, have moved to earlier transplant for severe alcohol-associated hepatitis with mandatory addiction treatment integration and post-transplant abstinence monitoring. NCD 260.1 itself does not impose a specific abstinence period; the standard is medical necessity and center-specific protocols.

Liver allocation operates on the MELD score (Model for End-Stage Liver Disease, originally MELD-Na incorporating sodium, more recently MELD 3.0 incorporating sex and other refinements). MELD ranges from 6 (relatively healthy) to 40 (extremely sick). Exceptions for HCC within criteria provide MELD exception points to allow listing. Acute liver failure carries Status 1A (highest priority) listing.

Emory Transplant Center has performed liver transplants since 1987 and is one of the higher-volume liver programs in the Southeast. Piedmont Transplant Institute is the second Georgia Medicare-approved adult liver transplant center, with a strong living donor liver transplant program.

Lung transplant: Section 1861(s)(2)(P) and the Emory program

Section 1861(s)(2)(P) of the Social Security Act provides specific authorization for lung and heart-lung transplantation as Medicare-covered services. Indications include idiopathic pulmonary fibrosis (now the leading lung transplant indication), chronic obstructive pulmonary disease, cystic fibrosis, pulmonary arterial hypertension, sarcoidosis with end-stage lung involvement, and selected occupational lung diseases.

Lung allocation operates on the Lung Allocation Score (LAS), implemented in 2005 to replace prior waiting-time-based allocation. LAS considers urgency (predicted waiting list mortality) and post-transplant survival to assign a composite score that determines priority within the geographic allocation region. Bilateral lung transplant is generally preferred for younger, healthier candidates (better long-term survival, particularly for cystic fibrosis where bilateral is required); single lung transplant is often considered for older candidates with comorbidities (shorter recovery, less complex surgery, organ-sparing impact).

Emory is the only Medicare-approved lung transplant center in Georgia. Georgia lung transplant candidates from outside Atlanta must coordinate evaluation, surgery, and intensive post-transplant follow-up at Emory, often requiring extended Atlanta stays for the first several months post-transplant.

Pancreas transplant: typically simultaneous pancreas-kidney for diabetic ESRD

Pancreas transplantation is most commonly performed as simultaneous pancreas-kidney (SPK) transplant for individuals with type 1 diabetes complicated by diabetic nephropathy progressing to ESRD. SPK provides both insulin independence (from the pancreas) and freedom from dialysis (from the kidney) in a single operation with a single immunosuppression regimen. Pancreas-after-kidney (PAK) and pancreas-transplant-alone (PTA) are performed in selected patients but are less common. Emory is the primary Georgia SPK center.

Intestinal and multi-visceral transplant: NCD 260.4

National Coverage Determination 260.4 (Intestinal and Multi-Visceral Transplantation) was promulgated in 2001. Intestinal transplant is performed for intestinal failure (typically from short-bowel syndrome from inflammatory bowel disease, mesenteric ischemia, or trauma; congenital intestinal anomalies in pediatrics; severe motility disorders) where total parenteral nutrition has failed (TPN-associated liver disease, recurrent line sepsis, loss of vascular access). Multi-visceral transplant combines intestine with liver and/or stomach and/or pancreas. Fewer than 150 intestinal/multi-visceral transplants are performed nationally per year. No Georgia centers currently perform intestinal transplant; Georgia patients are referred to the University of Pittsburgh Medical Center, Jackson Memorial Hospital in Miami, or Indiana University in Indianapolis.

Stem cell transplantation: NCD 110.8.1

National Coverage Determination 110.8.1 (Stem Cell Transplantation: Allogeneic and Autologous) establishes Medicare coverage for hematopoietic stem cell transplantation including bone marrow harvest, peripheral blood stem cell collection (apheresis), and umbilical cord blood transplantation. Covered indications include acute myeloid leukemia and acute lymphoblastic leukemia in appropriate remission status, chronic myeloid leukemia for select patients (since tyrosine kinase inhibitors have largely replaced transplant for first-line CML), multiple myeloma (autologous transplant remains standard of care for eligible patients), Hodgkin and non-Hodgkin lymphomas (autologous transplant for chemosensitive relapse, allogeneic for selected cases), myelodysplastic syndrome (allogeneic transplant for IPSS-R intermediate to very high risk), severe aplastic anemia, sickle cell disease (NCD recently expanded), and selected non-malignant conditions.

Stem cell transplant is performed at specialized centers with the infrastructure to manage prolonged neutropenia (4 weeks or more post-transplant), graft-versus-host disease prevention and treatment, opportunistic infection prophylaxis, and the multidisciplinary care required for the transplant process. In Georgia, Emory Winship Cancer Institute, Northside Hospital Atlanta, and Children's Healthcare of Atlanta are the primary stem cell transplant programs.

Section 1861(v)(1)(F): organ acquisition cost reimbursement

Section 1861(v)(1)(F) of the Social Security Act and 42 CFR 412.100 and 413.200 establish the reimbursement methodology for organ acquisition costs. Unlike most Medicare hospital payments which are bundled into DRG-based prospective payment, organ acquisition costs are paid on a reasonable cost basis. This recognizes that organ procurement is logistically and clinically unique, varies substantially across organs and centers, and cannot be efficiently bundled into a single prospective payment.

Standard Acquisition Charge methodology

Each Medicare-approved transplant center calculates an annual Standard Acquisition Charge (SAC) for each organ program. The SAC includes organ procurement organization fees (the OPO charges the center for organ recovery, transport, and associated services), recipient evaluation costs (the multi-month workup that precedes listing), donor evaluation costs (for living donor programs), organ recovery surgery costs, organ transport costs (often by air for cross-country organ movement), tissue typing and crossmatching, and administrative overhead. Total annual organ acquisition costs are divided by the number of transplants performed to yield the per-transplant SAC.

The SAC is billed by the transplant center to Medicare separately from the inpatient DRG payment for the transplant admission. This means that for a kidney transplant, Medicare pays Emory approximately $120,000 to $150,000 under the DRG plus approximately $95,000 under the SAC, for a combined Medicare payment of approximately $215,000 to $245,000 for the transplant episode itself, with additional payments for post-transplant outpatient care, immunosuppressives, and follow-up.

LifeLink of Georgia: the organ procurement organization

LifeLink of Georgia (404-636-1100) is the federally designated organ procurement organization for the state of Georgia. OPOs are designated by the Centers for Medicare and Medicaid Services to serve specific geographic Donor Service Areas (DSAs), and LifeLink covers the entire state of Georgia (the DSA for organ recovery purposes, though allocation has shifted to circle-based and continuous distribution models away from rigid DSA boundaries).

LifeLink's responsibilities include identification of potential deceased donors through hospital donation coordinator networks, family approach and authorization for donation, donor management (maintaining hemodynamics and organ function in the deceased donor in ICU), organ recovery surgery (with LifeLink-affiliated surgeons traveling to the donor hospital), tissue typing and crossmatching, organ transport coordination, and billing of recipient transplant centers for acquisition costs. LifeLink is reimbursed by transplant centers (which are reimbursed by Medicare under Section 1861(v)(1)(F)). LifeLink operates organ procurement, eye procurement, and tissue procurement services for Georgia.

UNOS allocation: the United Network for Organ Sharing

The Organ Procurement and Transplantation Network (OPTN), administered under contract with the federal Health Resources and Services Administration by the United Network for Organ Sharing (UNOS) under authority of Section 1138 of the Social Security Act and the National Organ Transplant Act of 1984 (Public Law 98-507), governs how deceased-donor organs are allocated to candidates on transplant waiting lists. UNOS does not own or possess organs; UNOS operates the allocation algorithms and the central match-run system that connects donor organs (offered by OPOs after recovery) with the highest-priority compatible candidate on the waiting list.

The UNOS allocation system varies by organ. Kidney allocation (Kidney Allocation System, KAS, originally implemented December 2014, revised 2021) uses a points-based system that considers blood type matching, HLA matching, expected post-transplant survival (EPTS) score for the candidate compared with the Kidney Donor Profile Index (KDPI) for the kidney, time on dialysis (which counts retroactively from dialysis start for patients listed within 1 year of dialysis initiation), prior living donation history (highest priority for living kidney donors who later develop ESRD), pediatric status (priority for children), and geographic distance from donor hospital to candidate center. Heart allocation uses the 2018 six-tier urgency system. Liver allocation uses MELD scoring with exceptions. Lung allocation uses LAS. All organ systems have moved away from rigid DSA boundaries to circle-based or continuous distribution models for geographic equity.

For Georgia transplant candidates, UNOS Region 3 (Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, Puerto Rico) is the relevant regional context historically, though circle-based allocation policies have moved organ movement increasingly across regional boundaries. Wait times vary by organ, blood type, sensitization, and individual patient factors.

42 CFR 482.68 through 482.104: Medicare Transplant Center Conditions of Participation

The Medicare Transplant Center Conditions of Participation were promulgated in the 2007 final rule published June 28, 2007, effective June 28, 2008, codified at 42 CFR 482.68 through 482.104. These regulations establish the standards transplant centers must meet to be Medicare-approved for each organ program.

42 CFR 482.68 (general): Each organ program (kidney, liver, heart, lung, pancreas, intestine) at a hospital must be separately approved. A hospital cannot be "Medicare-approved" for transplant globally; approval is organ-specific.

42 CFR 482.72 (volume requirements): Centers must meet minimum case volume during 12-month evaluation periods. Each organ program has different minimum volume thresholds. Volume requirements ensure that centers maintain sufficient surgical and clinical experience to deliver safe transplant care.

42 CFR 482.74 (outcome requirements): Centers must achieve 1-year patient and graft survival within statistically expected range based on risk-adjusted modeling from the Scientific Registry of Transplant Recipients (SRTR). The SRTR is operated by the Hennepin Healthcare Research Institute under contract with HRSA and publishes risk-adjusted center-specific outcomes that CMS uses for Conditions of Participation evaluation.

42 CFR 482.80 through 482.104: Specific clinical, organizational, quality assessment, and patient management requirements including informed consent processes, multidisciplinary care, transplant team qualifications, infection control, quality assessment and performance improvement, and patient and donor protections.

Loss of Medicare approval has substantial consequences. A center that fails CoP cannot perform Medicare-paid transplants until approval is restored, which forces Medicare beneficiaries to seek transplant care elsewhere or pay out of pocket. CMS has terminated transplant center approvals in documented cases, and several Georgia-adjacent programs have experienced approval challenges over the past decade.

Worked example one: Margaret 67 Atlanta kidney transplant Emory

Margaret 67 retired Atlanta Public Schools teacher, type 2 diabetes 14 years, ESRD starting 8 months ago with hemodialysis at Fresenius. Medicare based on age (enrolled at 65) plus Medigap Plan G with BlueCross BlueShield. Listed at Emory after multi-month evaluation. Receives deceased-donor kidney transplant after 3.5-year wait at age 67.

Medicare payment to Emory for the transplant episode:

• Inpatient DRG 652 (Kidney Transplant): approximately $135,000 Medicare payment
• Standard Acquisition Charge: approximately $95,000
• Total transplant episode Medicare payment to Emory: approximately $230,000

Margaret's costs for the transplant episode:

• Part A inpatient deductible: covered by Medigap Plan G after a small Plan G deductible
• Part B deductible: already met from year
• Net out-of-pocket: approximately $250 (Plan G deductible)

Margaret's ongoing costs (year 1 post-transplant):

• Tacrolimus 4 mg twice daily: ~$3,600/year retail, Medicare Part B pays 80%, Medigap pays 20%, Margaret pays $0
• Mycophenolate 1000 mg twice daily: ~$2,400/year retail, Medicare Part B pays 80%, Medigap pays 20%, Margaret pays $0
• Prednisone 5 mg daily: ~$60/year retail, Medicare Part B pays 80%, Medigap pays 20%, Margaret pays $0
• Post-transplant nephrology visits (initially weekly, then biweekly, then monthly): Part B 80%, Medigap 20%, Margaret pays $0
• Lab monitoring (tacrolimus levels weekly initially, then progressively less frequent): Part B clinical lab benefit, Medicare pays 100%, Margaret pays $0
• Total Margaret year 1 out-of-pocket: under $500

This is the modern transplant cost story for Medicare beneficiaries with Medigap: Medicare and Medigap together cover nearly the entire cost of the transplant and ongoing immunosuppression.

Worked example two: Robert 71 Savannah heart transplant Emory

Robert 71 retired insurance underwriter, ischemic cardiomyopathy after multiple myocardial infarctions, NYHA Class IV symptoms despite optimal medical therapy including dual-chamber ICD and CRT. Medicare based on age plus Medigap Plan G. Referred from Memorial Health Savannah to Emory Heart Transplant Program for evaluation. Listed Status 2 (stable advanced heart failure). After 3 months, hospitalized for cardiogenic shock, placed on temporary mechanical circulatory support (Impella 5.5), escalated to Status 1. Receives heart transplant after 4-month total wait.

Medicare payment to Emory for the transplant episode:

• Inpatient DRG 1 or 2 (Heart Transplant or Implant of Heart Assist System): approximately $700,000 Medicare payment
• Standard Acquisition Charge: approximately $70,000
• Total: approximately $770,000

Robert's costs:

• Part A inpatient deductible: covered by Medigap
• Part B deductible and ongoing 20% coinsurance: covered by Medigap
• Net Robert year 1 out-of-pocket: under $500

Ongoing immunosuppression for Robert is typically more intensive than for kidney recipients: tacrolimus + mycophenolate + prednisone often supplemented by additional agents, plus frequent endomyocardial biopsies (12+ in the first year via right heart catheterization), surveillance coronary angiography for cardiac allograft vasculopathy, and intensive cardiology follow-up at Emory.

Worked example three: Linda 68 Macon liver transplant Piedmont alcoholic cirrhosis

Linda 68 retired nurse, alcohol use disorder with 30+ years of heavy drinking culminating in alcoholic cirrhosis. MELD 28 at evaluation with hepatic encephalopathy and ascites. 7 months sustained abstinence documented through PEth biomarker testing and weekly outpatient AUD treatment at Piedmont. Listed at Piedmont Transplant Institute. Receives deceased-donor liver transplant after 8-month wait.

Medicare payment to Piedmont:

• Inpatient DRG (Liver Transplant): approximately $400,000 Medicare payment
• Standard Acquisition Charge: approximately $95,000
• Total: approximately $495,000

Linda's costs:

• Part A deductible covered by Medigap Plan G
• Ongoing AUD treatment continuation post-transplant under Part B mental health benefit (Section 1861(s)(3)): covered with standard 20% coinsurance/Medigap
• Year 1 out-of-pocket: under $500

Linda's case illustrates the evolved approach to alcohol-associated liver disease: documented abstinence, integrated addiction treatment, and continued treatment post-transplant rather than abandonment.

Worked example four: Charles 73 Augusta lung transplant Emory IPF

Charles 73 retired automotive plant worker, idiopathic pulmonary fibrosis diagnosed 4 years ago, FVC declining to 50% predicted despite antifibrotic therapy (pirfenidone then nintedanib). Medicare based on age plus Medigap Plan F (grandfathered). Referred from MCG Health Augusta to Emory Lung Transplant Program. Listed with LAS 42. Receives bilateral lung transplant after 7-month wait.

Medicare payment to Emory:

• Inpatient DRG (Lung Transplant): approximately $620,000 Medicare payment
• Standard Acquisition Charge (bilateral): approximately $90,000
• Total: approximately $710,000

Charles's costs:

• Part A deductible covered by Medigap Plan F
• Post-transplant pulmonary rehabilitation under Section 1861(s)(2)(FF): Part B 80%, Medigap 20%
• Year 1 out-of-pocket: under $500

Charles's transition from Augusta to Atlanta for surgery and 3-month post-transplant intensive follow-up required temporary Atlanta housing, which is not a Medicare-covered cost. His family arranged housing through the Mason Guest House at Emory (transplant-specific patient housing). For families without resources, transplant social workers at Emory help identify housing options including the Hope Lodge American Cancer Society facility for selected oncology-related transplants and other community resources.

Worked example five: Patricia 58 Columbus ESRD pre-65 SSDI Medicare kidney waitlist Part B-ID

Patricia 58 worked as a Columbus middle school teacher until disabled by progressive focal segmental glomerulosclerosis. Qualified for SSDI at age 54 and became Medicare-eligible at age 56 after 24-month waiting period. Developed ESRD at age 55 with kidney biopsy diagnosis. ESRD-based Medicare entitlement began in month 4 of dialysis at age 55, providing dual Medicare basis (SSDI and ESRD).

Patricia waits 3 years on the kidney transplant list at Emory. Receives deceased-donor kidney transplant at age 58.

Post-transplant Medicare timeline:

• Month 1 post-transplant: Medicare entitlement continues based on both SSDI and ESRD
• Months 1-36 post-transplant: standard Medicare with Part A, Part B, Part D
• Month 37 post-transplant: ESRD-based component of Medicare entitlement terminates per Section 1881
• BUT: Patricia's SSDI-based Medicare entitlement continues independently
• Patricia retains full Medicare based on SSDI through age 65 transition to age-65 Medicare

If Patricia did NOT have SSDI-based Medicare and her Medicare was ESRD-only:

• Month 37 post-transplant: ESRD-based Medicare would terminate
• Patricia would enroll in Part B-ID under Section 402 of the CAA 2021
• Part B-ID premium: monthly premium applies
• Part B-ID deductible: annual deductible applies
• Immunosuppressive coverage: 80% by Part B-ID, 20% by patient (or Medigap if held)
• Pre-Section-402: Patricia would have lost coverage at month 37 and faced significant out-of-pocket immunosuppressive costs
• Post-Section-402: Patricia maintains coverage through Part B-ID indefinitely

Worked example six: Henry 70 rural Tifton simultaneous pancreas-kidney Emory

Henry 70 retired farmer, type 1 diabetes since age 14 (56 years duration), diabetic nephropathy progressing to ESRD on hemodialysis for 18 months. Listed for simultaneous pancreas-kidney transplant at Emory. Receives SPK after 18-month wait.

Medicare payment to Emory:

• Inpatient DRG 008 (Simultaneous Pancreas/Kidney Transplant): approximately $500,000 Medicare payment
• Standard Acquisition Charge (combined kidney + pancreas): approximately $165,000
• Total: approximately $665,000

Henry's costs:

• Part A deductible: covered by Medigap Plan G
• 200-mile ground transport from Tifton to Atlanta for surgery and follow-up: non-emergent transport not Medicare-covered; Henry pays approximately $200 per round trip via private medical transport or family driver
• Post-SPK insulin independence: Henry no longer requires insulin or insulin pump (pancreas success)
• Post-SPK dialysis independence: Henry no longer requires hemodialysis (kidney success)
• Lifetime savings from avoided insulin ($3,000/year previously) and avoided dialysis ($90,000/year previously)
• Year 1 out-of-pocket: approximately $2,500 (Plan G deductible + transport costs)

For dual-eligible Medicare/Medicaid beneficiaries in Henry's situation, Georgia Medicaid would cover non-emergent transport through DCH non-emergency medical transportation benefit (1-866-211-0950). Henry has not pursued Medicaid because his retirement income exceeds limits.

Fourteen common mistakes in Medicare transplant navigation

Mistake 1: Not enrolling in Part B-ID before ESRD-based Medicare ends at 36 months post-transplant. Beneficiaries whose sole Medicare basis is ESRD must enroll in Part B-ID during their initial enrollment period (the 8 months surrounding their Medicare termination) or face gaps in immunosuppressive coverage. Plan ahead before the 36-month cutoff.

Mistake 2: Assuming Part D covers transplant immunosuppressives. For Medicare-paid transplants, immunosuppressives are Part B drugs under Section 1861(s)(2)(J), not Part D. This affects cost-sharing structure, prior authorization processes, and Medigap coverage.

Mistake 3: Going to a non-Medicare-approved transplant center expecting Medicare to pay. Medicare will not pay for transplant at non-approved centers. Verify approval at the specific organ program level before pursuing transplant.

Mistake 4: Failing to maintain documented alcohol abstinence for liver transplant evaluation. Most centers and Medicare require documented abstinence with biomarker confirmation (PEth, ethyl glucuronide) and addiction treatment. Modern practice has evolved to permit earlier transplant for severe alcohol-associated hepatitis with intensive addiction treatment, but standard alcoholic cirrhosis still requires abstinence documentation.

Mistake 5: Stopping immunosuppressives due to cost concerns post-CAA-2021. Section 402 eliminated the historic coverage gap. Part B-ID is available; help is available; do not stop immunosuppressives. Contact your transplant center social worker, the National Kidney Foundation, or GeorgiaCares SHIP if cost is a barrier.

Mistake 6: Confusing dialysis Medicare entitlement (begins month 4) with transplant Medicare entitlement (begins month of transplant). Different timing rules apply. Patients pursuing preemptive transplant (transplant before dialysis) have different Medicare timing than patients who dialyzed first.

Mistake 7: Not understanding that 36-month ESRD termination only affects those whose sole Medicare basis is ESRD. Beneficiaries with concurrent age-65 or SSDI 24-month Medicare retain Medicare under those bases regardless of transplant outcome.

Mistake 8: Believing Medicare does not pay for living donor evaluation and surgery. Medicare DOES pay for living donor costs through the recipient's Medicare. The recipient's Medicare covers donor evaluation, donor surgery, and 90 days of post-donation follow-up.

Mistake 9: Not pursuing simultaneous pancreas-kidney (SPK) when eligible. Type 1 diabetics with ESRD often benefit more from SPK than kidney-alone transplant: both insulin independence and dialysis independence in a single operation with a single immunosuppression regimen.

Mistake 10: Missing LAS or MELD recalculation deadlines. Lung allocation requires LAS updates; liver allocation requires MELD updates. Failing to update can drop wait list status. Transplant coordinators typically manage this but patients should confirm.

Mistake 11: Failing to address transportation and housing logistics for travel to Atlanta transplant centers. Rural Georgia patients often need extended Atlanta stays for evaluation, surgery, and 3-month post-transplant intensive follow-up. Transplant social workers can help identify housing resources.

Mistake 12: Not enrolling in Medigap Plan G before turning 65 to cover 20% Part B coinsurance on lifetime immunosuppressives. Medigap initial enrollment period is the best window for guaranteed-issue Medigap. Without Medigap, the 20% coinsurance on lifetime immunosuppressives accumulates.

Mistake 13: Assuming Medicare Advantage plan covers transplant equivalently to Original Medicare. MA plans must cover transplant but may have restricted network of approved centers. Verify network and prior authorization before transplant evaluation.

Mistake 14: Not addressing oral health pre-transplant. Medicare does not cover routine dental but pre-transplant dental clearance is often required by centers (untreated dental infection becomes catastrophic under immunosuppression). May need out-of-pocket payment or dental Medicaid for dual-eligibles.

Medicare Advantage and transplant coverage

Medicare Advantage plans (Part C) must cover all services that Original Medicare covers, including transplant services. However, MA plans operate with network restrictions and prior authorization processes that can affect transplant access. Key considerations:

Network: MA plans may have a defined network of approved transplant centers. Before pursuing transplant evaluation, verify that the MA plan's network includes a Medicare-approved center for the relevant organ. In Georgia, Emory and Piedmont are in most MA plan networks but always verify directly.

Prior authorization: MA plans typically require prior authorization for transplant evaluation, listing, and surgery. The transplant center submits authorization requests; delays in authorization can affect care timing.

Out-of-network exceptions: MA plans must cover medically necessary care at out-of-network providers when no in-network option exists. If an MA plan does not have a Medicare-approved heart transplant center in its network, the plan must cover heart transplant at an out-of-network Medicare-approved center.

Pharmacy benefit interaction: Most MA plans include Part D drug coverage. However, transplant immunosuppressives are Part B drugs (not Part D) for Medicare-paid transplants. This means immunosuppressives flow through the MA plan's medical benefit, not its pharmacy benefit, even though they are oral medications.

Dual-eligible Medicare/Medicaid and transplant

For Georgia residents who qualify for both Medicare and Medicaid (Qualified Medicare Beneficiary, Specified Low-Income Medicare Beneficiary, Qualifying Individual, or full-benefit dual-eligibility), Medicaid provides important supplementary coverage for transplant care:

Medicare Part A and B cost-sharing: Medicaid covers Medicare deductibles, coinsurance, and copayments for dual-eligibles, eliminating the typical patient out-of-pocket.

Part B-ID premium and cost-sharing: For kidney transplant recipients whose Medicare ended at 36 months post-transplant, Medicaid can cover Part B-ID premium and 20% coinsurance.

Non-emergency medical transportation: Georgia Medicaid covers NEMT through DCH for transplant evaluation and post-transplant follow-up visits, addressing the rural travel barrier to Atlanta transplant centers.

Dental clearance: Georgia Medicaid limited adult dental coverage (DCH 1-866-211-0950) may help with pre-transplant dental work for full-benefit dual-eligibles.

Drug coverage: Medicaid drug coverage supplements Medicare for drugs not covered by Medicare (e.g., over-the-counter products) and may help with high-cost drugs not on Part D formularies.

Appeals and the right to challenge Medicare transplant decisions

Medicare transplant coverage decisions, including denial of transplant evaluation authorization, denial of organ acquisition cost payment, or termination of post-transplant immunosuppressive coverage, are subject to the standard Medicare appeals process. Five levels of appeal are available:

Level 1 (Redetermination): Within 120 days of the initial determination, the beneficiary or provider can request redetermination by the Medicare Administrative Contractor (Palmetto GBA for Georgia, Jurisdiction J, 1-877-567-9230).

Level 2 (Reconsideration): If redetermination is unfavorable, within 180 days the beneficiary can request reconsideration by a Qualified Independent Contractor (QIC).

Level 3 (Administrative Law Judge): If reconsideration is unfavorable and the amount in controversy meets the applicable threshold, within 60 days the beneficiary can request an ALJ hearing through the Office of Medicare Hearings and Appeals.

Level 4 (Medicare Appeals Council): If the ALJ decision is unfavorable, within 60 days the beneficiary can request Medicare Appeals Council review at the Departmental Appeals Board.

Level 5 (Federal District Court): If the Council decision is unfavorable and the amount in controversy meets the applicable threshold, the beneficiary can file suit in federal district court.

For urgent transplant-related appeals where delay could result in clinical deterioration or transplant ineligibility, the beneficiary can request expedited review at any level. For practical assistance with Medicare appeals, Georgia beneficiaries can contact the Medicare Rights Center at 1-800-333-4114, the Center for Medicare Advocacy at 1-860-456-7790, or GeorgiaCares SHIP at 1-866-552-4464.

How Brevy helps Georgia families navigate Medicare transplant care

Brevy (brevy.com) is the eldercare resource helping Georgia families understand and navigate the intersection of federal Medicare entitlement rules, organ-specific coverage policies, Medicare-approved transplant center designation, organ acquisition cost reimbursement, the Section 402 Part B-ID immunosuppressive drug benefit, UNOS allocation, post-transplant care coordination, dual-eligibility coordination, and the practical realities of pursuing transplant care across Georgia's geography. Transplant care is among the most complex Medicare coverage areas, involving statutory provisions spanning decades, regulatory standards across multiple parts of the CFR, NCDs that vary by organ, and a separate organ allocation system administered by UNOS under federal contract. Brevy's mission is to translate this complexity into actionable understanding for the patients, family members, and care coordinators making transplant decisions in real time.

Find personalized help navigating Medicare transplant coverage in Georgia at brevy.com.

::: accordion Q1: What is Section 1881(b) of the Social Security Act and how does it relate to kidney transplant?

Section 1881(b), added by Public Law 92-603 in 1972 (the Social Security Amendments of 1972), establishes Medicare entitlement for individuals with end-stage renal disease regardless of age. This is the only Medicare entitlement pathway tied to a specific disease (rather than age 65+ or SSDI disability for 24+ months). For kidney transplant candidates and recipients, Section 1881(b) provides the Medicare coverage framework: entitlement begins in the 4th month of dialysis or in the month of preemptive transplant, and historically terminated 36 months after successful transplant for those whose sole Medicare basis was ESRD.

Q2: What is Part B-ID and how does Section 402 of the Consolidated Appropriations Act 2021 work?

Part B-ID (Part B Immunosuppressive Drug benefit) was created by Section 402 of the Consolidated Appropriations Act 2021, Public Law 116-260, signed by President Trump December 27, 2020, with the immunosuppressive drug provision effective January 1, 2023. Part B-ID permanently extends Medicare coverage of immunosuppressive drugs beyond the 36-month ESRD termination cutoff that previously caused kidney transplant recipients to lose coverage and risk transplant rejection. Part B-ID is a standalone benefit with its own monthly premium, annual deductible, and 20% coinsurance. Eligibility: kidney transplant paid by Medicare, broader Medicare entitlement has ended, no creditable coverage from other sources, and timely enrollment.

Q3: When does Medicare entitlement begin for kidney transplant candidates?

For patients on dialysis who later receive transplant: Medicare ESRD entitlement began in the 4th month of dialysis. For patients receiving preemptive transplant (transplant before dialysis): Medicare entitlement begins in the month of transplant or up to 2 months before if hospitalized for transplant preparation. For patients with concurrent age-65 or SSDI-based Medicare: that pre-existing Medicare continues alongside ESRD-based Medicare.

Q4: Which transplant centers in Georgia are Medicare-approved for kidney transplant?

Emory Transplant Center (855-366-7989), Piedmont Transplant Institute (404-605-3232), Augusta University Transplant (706-721-2888), and Children's Healthcare of Atlanta (404-785-4150, pediatric only) are Medicare-approved kidney transplant centers in Georgia.

Q5: Which Georgia centers perform heart transplant?

Emory University Hospital is the only Medicare-approved heart transplant center in Georgia. Contact the Emory Heart Transplant Program through the central Emory Transplant Center number at 855-366-7989.

Q6: Which Georgia centers perform liver transplant?

Emory Transplant Center and Piedmont Transplant Institute are the two Medicare-approved adult liver transplant centers in Georgia. Children's Healthcare of Atlanta performs pediatric liver transplant.

Q7: Which Georgia center performs lung transplant?

Emory is the only Medicare-approved lung transplant center in Georgia, serving patients with idiopathic pulmonary fibrosis, COPD, cystic fibrosis, pulmonary hypertension, and other indications.

Q8: What is the Standard Acquisition Charge and how does it work?

The Standard Acquisition Charge (SAC) is the per-transplant amount that Medicare pays to transplant centers for organ acquisition costs, separately from the inpatient DRG payment for the transplant admission. SAC is calculated annually by each center by dividing total annual organ acquisition costs (OPO fees, recipient evaluation, donor evaluation, organ recovery, organ transport, tissue typing, crossmatching, administrative overhead) by the number of transplants performed.

Q9: What is LifeLink of Georgia?

LifeLink of Georgia (404-636-1100) is the federally designated organ procurement organization for the state of Georgia. LifeLink coordinates organ recovery from deceased donors, manages tissue typing and crossmatching, transports organs to transplant centers, and bills centers for acquisition costs under the Section 1861(v)(1)(F) reimbursement methodology.

Q10: What is UNOS and how does organ allocation work?

The United Network for Organ Sharing (UNOS, 1-888-894-6361) administers the Organ Procurement and Transplantation Network under contract with HRSA, operating the allocation algorithms that match deceased-donor organs to candidates on transplant waiting lists. Kidney allocation uses the Kidney Allocation System (KAS, points-based with EPTS/KDPI). Heart uses a 6-tier urgency system. Liver uses MELD scoring. Lung uses Lung Allocation Score. All systems have moved away from rigid DSA boundaries to circle-based or continuous distribution models.

Q11: How long is the kidney transplant waiting list in Georgia?

Wait times for deceased-donor kidney in UNOS Region 3 (which includes Georgia) vary by blood type, sensitization, EPTS, geographic distance, and individual factors. Living donation can reduce wait time significantly for medically suitable recipient/donor pairs.

Q12: What immunosuppressive drugs does Medicare cover?

Medicare Part B covers tacrolimus (Prograf, Astagraf, Envarsus), cyclosporine (Sandimmune, Neoral, Gengraf), sirolimus (Rapamune), everolimus (Zortress), mycophenolate (CellCept, Myfortic), azathioprine (Imuran), prednisone, basiliximab (Simulect, J0480), antithymocyte globulin (Thymoglobulin, J7504), belatacept (Nulojix, J0490), rituximab (Rituxan, J9312), and eculizumab (Soliris, J1300) when used for Medicare-paid transplant recipients.

Q13: What is the cost of immunosuppressive drugs without insurance coverage?

Annual retail cost of typical maintenance immunosuppression (tacrolimus + mycophenolate + prednisone) is approximately $6,000 to $25,000 depending on dose, brand vs. generic, and individual factors. Without Medicare/insurance coverage, this is the out-of-pocket burden that historically caused transplant rejection cases pre-Section-402.

Q14: Does Medicare cover living donor surgery costs?

Yes. Medicare covers living donor evaluation, surgery, and 90 days of post-donation follow-up through the kidney transplant recipient's Medicare. The donor does not need separate Medicare coverage; the recipient's Medicare pays for donor care related to the donation.

Q15: What is simultaneous pancreas-kidney (SPK) transplant?

SPK is the simultaneous transplantation of pancreas and kidney into a single recipient, most commonly performed for individuals with type 1 diabetes complicated by diabetic nephropathy progressing to ESRD. SPK provides both insulin independence (from the pancreas) and dialysis independence (from the kidney) in a single operation with a single immunosuppression regimen. Emory is Georgia's primary SPK center.

Q16: Does Medicare cover stem cell transplant?

Yes. NCD 110.8.1 covers stem cell transplantation including allogeneic and autologous bone marrow, peripheral blood stem cell, and umbilical cord blood transplants for acute leukemia, multiple myeloma, lymphomas, myelodysplastic syndrome, severe aplastic anemia, sickle cell disease, and other indications. Emory Winship, Northside Hospital, and Children's Healthcare of Atlanta are primary Georgia stem cell transplant centers.

Q17: What is the difference between Original Medicare and Medicare Advantage for transplant?

MA plans must cover transplant services. However, MA plans operate with network restrictions and prior authorization processes. Verify that the MA plan's network includes a Medicare-approved transplant center for the relevant organ before pursuing transplant. MA plans must cover medically necessary care at out-of-network providers when no in-network option exists.

Q18: How does Medigap interact with transplant cost-sharing?

Medigap plans cover Part A and Part B cost-sharing including the Part A inpatient deductible, Part B annual deductible, and 20% Part B coinsurance. For lifetime immunosuppressive coverage under Part B, Medigap effectively eliminates out-of-pocket cost. Medigap initial enrollment period (the 6 months starting when you turn 65 and enroll in Part B) is the best window for guaranteed-issue Medigap.

Q19: What if I am dual-eligible for Medicare and Medicaid in Georgia?

For Georgia dual-eligibles, Georgia Medicaid (DCH 1-866-211-0950) covers Medicare Part A and B cost-sharing, the Part B-ID premium and cost-sharing for kidney transplant recipients post-36-months, non-emergency medical transportation to transplant centers, dental clearance for transplant evaluation (for full-benefit dual-eligibles), and other supplementary services.

Q20: How do I appeal a Medicare transplant denial?

Medicare appeals follow 5 levels: Redetermination by MAC (within 120 days), Reconsideration by QIC (within 180 days), ALJ hearing (within 60 days, minimum threshold applies), Medicare Appeals Council (within 60 days), Federal District Court (minimum threshold applies). For urgent matters, expedited review is available. Contact Medicare Rights Center (1-800-333-4114) or Center for Medicare Advocacy (1-860-456-7790) for help.

Q21: Does Medicare cover transportation to transplant centers?

Generally no. Medicare Part B covers emergency ambulance transport but not non-emergency transport for routine visits. Medicare Advantage plans may offer limited transportation benefits. Medicaid for dual-eligibles covers non-emergency medical transportation through DCH. Private transportation, family members, or community resources fill gaps for non-dual-eligibles.

Q22: Does Medicare cover housing during extended transplant stays?

Generally no. Medicare does not cover patient housing during transplant evaluation, surgery, or post-transplant intensive follow-up periods. Transplant social workers help identify housing resources including center-specific guest houses (Emory's Mason Guest House), American Cancer Society Hope Lodge for selected oncology-related transplants, and community resources. Some MA plans offer limited housing benefits.

Q23: What is the alcohol abstinence requirement for liver transplant?

NCD 260.1 does not impose a specific abstinence period; medical necessity and center-specific protocols govern. Historically most centers required 6 months minimum sustained abstinence for alcohol-associated liver disease. Modern practice has evolved: some centers permit earlier transplant for severe alcohol-associated hepatitis (acute presentation) with intensive integrated addiction treatment and post-transplant abstinence monitoring. Standard alcoholic cirrhosis evaluation still typically requires documented abstinence with biomarker confirmation (PEth, ethyl glucuronide).

Q24: How do I prepare for transplant evaluation?

(1) Confirm Medicare-approved status of the target center for your organ. (2) Discuss referral with your treating specialist (nephrologist for kidney, cardiologist for heart, hepatologist for liver, pulmonologist for lung). (3) Address known contraindications: tobacco cessation (often required pre-listing), alcohol abstinence documentation for liver, dental clearance, infectious disease screening, oncologic screening. (4) Pursue any additional insurance coverage including Medigap if Medicare-eligible. (5) Prepare for multi-month evaluation including cardiopulmonary testing, imaging, psychosocial evaluation, and committee review.

Q25: Where can I get help understanding my Medicare transplant options in Georgia?

Contact GeorgiaCares SHIP at 1-866-552-4464 for free Medicare counseling. Contact your target transplant center's social worker for center-specific guidance. Contact the National Kidney Foundation at 1-800-622-9010 for kidney transplant resources. Contact the American Transplant Foundation at 1-800-385-1283 for cross-organ resources. Contact Brevy at brevy.com for educational content on Medicare transplant coverage. :::

::: cta Georgia and federal contacts for Medicare transplant services

• Medicare: 1-800-MEDICARE (1-800-633-4227); 24/7
• Palmetto GBA Jurisdiction J MAC: 1-877-567-9230
• GeorgiaCares SHIP (free Medicare counseling): 1-866-552-4464
• Georgia DCH Medicaid Member Services: 1-866-211-0950
• Emory Transplant Center: 855-366-7989 (kidney, liver, heart, lung, pancreas, stem cell)
• Piedmont Transplant Institute: 404-605-3232 (kidney, liver, living donor)
• Augusta University Transplant: 706-721-2888 (adult and limited pediatric kidney)
• Children's Healthcare of Atlanta Transplant Services: 404-785-4150 (pediatric kidney, heart, liver, stem cell)
• LifeLink of Georgia (organ procurement organization): 404-636-1100
• UNOS Patient Services: 1-888-894-6361
• National Kidney Foundation: 1-800-622-9010
• American Transplant Foundation: 1-800-385-1283
• Medicare Rights Center: 1-800-333-4114
• Center for Medicare Advocacy: 1-860-456-7790
• Kepro QIO (Beneficiary and Family Centered Care): 1-844-455-8708
• Atlanta Legal Aid: 404-377-0701
• Georgia Legal Services: 1-800-498-9469
• 211 Georgia: 211
• Eldercare Locator: 1-800-677-1116
• VA Benefits: 1-800-827-1000
• Social Security: 1-800-772-1213
• HHS OCR (civil rights complaints): 1-800-368-1019 :::